K. UYGUN Et Al. , "XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.," Asian Pacific journal of cancer prevention : APJCP , vol.14, pp.2283-8, 2013
UYGUN, K. Et Al. 2013. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.. Asian Pacific journal of cancer prevention : APJCP , vol.14 , 2283-8.
UYGUN, K., BILICI, A., KAYA, S., Oven, U., YILDIZ, R., TEMIZ, S., ... Seker, M.(2013). XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.. Asian Pacific journal of cancer prevention : APJCP , vol.14, 2283-8.
UYGUN, K Et Al. "XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.," Asian Pacific journal of cancer prevention : APJCP , vol.14, 2283-8, 2013
UYGUN, K Et Al. "XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.." Asian Pacific journal of cancer prevention : APJCP , vol.14, pp.2283-8, 2013
UYGUN, K. Et Al. (2013) . "XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.." Asian Pacific journal of cancer prevention : APJCP , vol.14, pp.2283-8.
@article{article, author={K UYGUN Et Al. }, title={XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.}, journal={Asian Pacific journal of cancer prevention : APJCP}, year=2013, pages={2283-8} }